BR112013000776A2 - método e formulação para tratamento de deficiência de ácido siálico - Google Patents
método e formulação para tratamento de deficiência de ácido siálicoInfo
- Publication number
- BR112013000776A2 BR112013000776A2 BR112013000776A BR112013000776A BR112013000776A2 BR 112013000776 A2 BR112013000776 A2 BR 112013000776A2 BR 112013000776 A BR112013000776 A BR 112013000776A BR 112013000776 A BR112013000776 A BR 112013000776A BR 112013000776 A2 BR112013000776 A2 BR 112013000776A2
- Authority
- BR
- Brazil
- Prior art keywords
- formulation
- sialic acid
- treatment
- acid deficiency
- deficiency
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 238000009472 formulation Methods 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 title abstract 2
- 230000007812 deficiency Effects 0.000 title abstract 2
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 title abstract 2
- 238000013268 sustained release Methods 0.000 abstract 1
- 239000012730 sustained-release form Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2063—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Biophysics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36399510P | 2010-07-13 | 2010-07-13 | |
| PCT/US2011/043910 WO2012009474A1 (en) | 2010-07-13 | 2011-07-13 | Method and formulations for treating sialic acid deficiencies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112013000776A2 true BR112013000776A2 (pt) | 2016-05-24 |
Family
ID=45469794
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112013000776A BR112013000776A2 (pt) | 2010-07-13 | 2011-07-13 | método e formulação para tratamento de deficiência de ácido siálico |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US9511015B2 (enExample) |
| EP (1) | EP2593109A4 (enExample) |
| JP (1) | JP5777712B2 (enExample) |
| KR (1) | KR20140003380A (enExample) |
| CN (2) | CN108606956A (enExample) |
| AU (1) | AU2011279158B2 (enExample) |
| BR (1) | BR112013000776A2 (enExample) |
| CA (1) | CA2805222A1 (enExample) |
| IL (1) | IL224203B (enExample) |
| WO (1) | WO2012009474A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9241896B2 (en) | 2008-12-19 | 2016-01-26 | Ultragenyx Pharmaceutical Inc. | Methods and formulations for treating sialic acid deficiencies |
| AU2011279158B2 (en) | 2010-07-13 | 2015-07-09 | Ultragenyx Pharmaceutical Inc. | Method and formulations for treating sialic acid deficiencies |
| US8840926B2 (en) | 2011-10-24 | 2014-09-23 | Ultragenyx Pharmaceutical Inc. | Sialic acid analogs |
| EP2804600A4 (en) * | 2012-01-18 | 2015-09-02 | Ultragenyx Pharmaceutical Inc | METHODS AND FORMULATIONS FOR TREATING SIALIC ACID DEFICIENCIES |
| US20140057856A1 (en) * | 2012-08-22 | 2014-02-27 | The Regents Of The Universtiy Of California | Compositions and Methods For Enhancing Sialic Acid Levels In Tissue |
| EP4183806A3 (en) | 2014-11-12 | 2023-08-02 | Seagen Inc. | Glycan-interacting compounds and methods of use |
| WO2017048817A1 (en) | 2015-09-14 | 2017-03-23 | Ultragenyx Pharmaceutical Inc. | Crystal forms of sialic acid or salt or solvate thereof |
| CN108463248B (zh) | 2015-11-12 | 2022-10-21 | 西雅图基因公司 | 聚糖相互作用化合物及使用方法 |
| WO2018094143A1 (en) | 2016-11-17 | 2018-05-24 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
| WO2018160909A1 (en) | 2017-03-03 | 2018-09-07 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
| WO2019089533A1 (en) * | 2017-10-31 | 2019-05-09 | Once Labs Inc. | Determining, encoding, and transmission of classification variables at end-device for remote monitoring |
| EP3486326A1 (en) | 2017-11-21 | 2019-05-22 | Jennewein Biotechnologie GmbH | Method for the purification of n-acetylneuraminic acid from a fermentation broth |
| WO2019140147A1 (en) * | 2018-01-12 | 2019-07-18 | The Wistar Institute Of Anatomy And Biology | Methods for identifying and treating hiv persistence |
| CN110548012B (zh) * | 2019-08-27 | 2022-05-13 | 嘉必优生物技术（武汉）股份有限公司 | 一种唾液酸片剂及其制备方法 |
| TW202513040A (zh) * | 2023-09-01 | 2025-04-01 | 瑞士商赫孚孟拉羅股份公司 | 製備半固體組成物之新穎方法及其用途 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6168418A (ja) | 1984-09-11 | 1986-04-08 | Kanto Ishi Pharma Co Ltd | 去痰薬 |
| AU721276B2 (en) | 1995-04-04 | 2000-06-29 | Wound Healing Of Oklahoma | Cancer treatment by photodynamic therapy, in combination with an immunoadjuvant |
| US5624677A (en) | 1995-06-13 | 1997-04-29 | Pentech Pharmaceuticals, Inc. | Controlled release of drugs delivered by sublingual or buccal administration |
| WO1999052931A1 (fr) | 1998-04-10 | 1999-10-21 | Mitsubishi Chemical Corporation | Dispersion solide contenant un derive d'acide sialique |
| ATE503498T1 (de) * | 2002-06-21 | 2011-04-15 | Novo Nordisk Healthcare Ag | Pegylierte glykoformen von faktor vii |
| US7238677B2 (en) * | 2003-03-28 | 2007-07-03 | Kimberly-Clark Worldwide, Inc. | Prevention of urogenital infections |
| EP1697481A2 (en) | 2003-12-09 | 2006-09-06 | Spherics, Inc. | Bioadhesive polymers with catechol functionality |
| NZ561116A (en) * | 2005-03-03 | 2010-02-26 | Mannatech Inc | Methods and compositions for modified release of nutritional supplements |
| WO2007103286A2 (en) | 2006-03-02 | 2007-09-13 | Spherics, Inc. | Rate-controlled bioadhesive oral dosage formulations |
| WO2008027557A2 (en) | 2006-08-31 | 2008-03-06 | Spherics, Inc. | Topiramate compositions and methods of enhancing its bioavailability |
| CA2680842C (en) * | 2007-05-31 | 2015-11-24 | Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services National Institutes Of Health | N-acetyl mannosamine or derivatives thereof for use in treating a kidney disorder in a mammal |
| US20090081249A1 (en) * | 2007-08-27 | 2009-03-26 | Massachusetts Institute Of Technology | Bi-Functional Polymer-Attached Inhibitors of Influenza Virus |
| WO2009137827A2 (en) | 2008-05-09 | 2009-11-12 | Tiara Pharmaceuticals, Inc. | Controlled release of n-acetylcysteine (nac) for reduction of systemic and/or vascular inflammation |
| KR101116864B1 (ko) * | 2008-08-01 | 2012-02-29 | 주식회사 베네비오 | 고지혈증, 지방간 또는 비만의 예방 또는 치료용 조성물 |
| US20100159001A1 (en) * | 2008-12-19 | 2010-06-24 | Cardinal John R | Extended-Release Pharmaceutical Formulations |
| US9241896B2 (en) | 2008-12-19 | 2016-01-26 | Ultragenyx Pharmaceutical Inc. | Methods and formulations for treating sialic acid deficiencies |
| US20100160363A1 (en) | 2008-12-19 | 2010-06-24 | Aaipharma Services Corp. | Extended-release pharmaceutical formulations |
| JP5626734B2 (ja) * | 2009-05-15 | 2014-11-19 | 公益財団法人ヒューマンサイエンス振興財団 | Ｇｎｅタンパク質の機能低下に起因する疾患の治療用医薬剤、食品組成物 |
| AU2011279158B2 (en) | 2010-07-13 | 2015-07-09 | Ultragenyx Pharmaceutical Inc. | Method and formulations for treating sialic acid deficiencies |
| US8840926B2 (en) | 2011-10-24 | 2014-09-23 | Ultragenyx Pharmaceutical Inc. | Sialic acid analogs |
| EP2804600A4 (en) | 2012-01-18 | 2015-09-02 | Ultragenyx Pharmaceutical Inc | METHODS AND FORMULATIONS FOR TREATING SIALIC ACID DEFICIENCIES |
-
2011
- 2011-07-13 AU AU2011279158A patent/AU2011279158B2/en not_active Ceased
- 2011-07-13 WO PCT/US2011/043910 patent/WO2012009474A1/en not_active Ceased
- 2011-07-13 EP EP11807478.0A patent/EP2593109A4/en not_active Withdrawn
- 2011-07-13 CN CN201810170704.1A patent/CN108606956A/zh active Pending
- 2011-07-13 CA CA2805222A patent/CA2805222A1/en not_active Abandoned
- 2011-07-13 CN CN2011800439776A patent/CN103370069A/zh active Pending
- 2011-07-13 US US13/810,068 patent/US9511015B2/en active Active
- 2011-07-13 KR KR1020137003511A patent/KR20140003380A/ko not_active Ceased
- 2011-07-13 BR BR112013000776A patent/BR112013000776A2/pt not_active IP Right Cessation
- 2011-07-13 JP JP2013519806A patent/JP5777712B2/ja active Active
-
2013
- 2013-01-13 IL IL224203A patent/IL224203B/en not_active IP Right Cessation
- 2013-01-18 US US13/745,106 patent/US9554987B2/en not_active Expired - Fee Related
-
2016
- 2016-10-26 US US15/334,885 patent/US20170136051A1/en not_active Abandoned
- 2016-12-19 US US15/383,682 patent/US20170157160A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN103370069A (zh) | 2013-10-23 |
| KR20140003380A (ko) | 2014-01-09 |
| US20130273160A1 (en) | 2013-10-17 |
| AU2011279158A1 (en) | 2013-02-21 |
| US20170136051A1 (en) | 2017-05-18 |
| US9511015B2 (en) | 2016-12-06 |
| EP2593109A4 (en) | 2014-01-08 |
| CN108606956A (zh) | 2018-10-02 |
| CA2805222A1 (en) | 2012-01-19 |
| AU2011279158B2 (en) | 2015-07-09 |
| US9554987B2 (en) | 2017-01-31 |
| WO2012009474A1 (en) | 2012-01-19 |
| US20130225513A1 (en) | 2013-08-29 |
| IL224203B (en) | 2018-06-28 |
| JP2013531041A (ja) | 2013-08-01 |
| US20170157160A1 (en) | 2017-06-08 |
| JP5777712B2 (ja) | 2015-09-09 |
| EP2593109A1 (en) | 2013-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112013000776A2 (pt) | método e formulação para tratamento de deficiência de ácido siálico | |
| MX386489B (es) | Inhibidores de ibat para el tratamiento de enfermedades hepaticas. | |
| MX352328B (es) | Formulaciones orales de ester de testosterona y metodos para el tratamiento de la deficiencia de testosterona que comprende estos. | |
| CY1119596T1 (el) | Σταθερη φαρμακευτικη συνθεση και μεθοδοι χρησης αυτης | |
| CR20120413A (es) | Derivados de fumarato de ácido graso y sus usos | |
| UY32456A (es) | Composicion famaceutica, forma farmaceutica, procedimiento para su preparación, metodos de tratamiento | |
| UY33314A (es) | Derivados de acido 1-amino-2-ciclopropiletilboronico | |
| IN2014MN00948A (enExample) | ||
| CR20110407A (es) | Dicianopiridinas alquilamino-sustituidas y sus profármacos de éster de aminoácido | |
| PL2444081T3 (pl) | Kompozycja do leczenia chorób zapalnych, zawierająca kwas bosweliowy i kannabidiol | |
| MX391043B (es) | Formulaciones de anticuerpo y metodos. | |
| IN2014CN04634A (enExample) | ||
| BR112012032248A2 (pt) | composições de 5-etil-2-{4-[-4(-4-tetrazol-1-il-fenoximetil)-tiazol-2-il]-piperidin-1-il}-pirimidina | |
| MX339198B (es) | Composicion y metodo para tratar condiciones de la piel. | |
| SG191068A1 (en) | New form of administration of enkephalinase inhibitor | |
| BR112012007798A2 (pt) | microcápsulas estáveis e composição para aplicação tópica e método para a preparação de microcápsulas | |
| BR112014000634A2 (pt) | métodos para tratamento de incontinência associada com atividade sexual | |
| GT201400242A (es) | "nuevos compuestos de pirazol" | |
| BR112014017587A8 (pt) | métodos e formulações para o tratamento de deficiências de ácido siálico | |
| BR112014009760A8 (pt) | análogos de ácido siálico | |
| MX2012007142A (es) | Uso de 2,3-dihidroxipropil dodecanoato para tratar seborrea. | |
| CO7121334A2 (es) | Formulaciones vesiculares | |
| AR093717A1 (es) | Composiciones y metodos para el tratamiento de la caries dental | |
| IN2014DN10658A (enExample) | ||
| AU2012307449A8 (en) | Sulfonic acid salts of heterocyclylamide-substituted imidazoles |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2522 DE 07-05-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |